$ATRA
Atara Biotherapeutics, Inc.

2015 Q2 Form 10-Q Financial Statement

#000156459015006518 Filed on August 07, 2015

View on sec.gov

Income Statement

Concept 2015 Q2 2014 Q4 2014 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.600M $5.550M $1.360M
YoY Change 164.71% 72.15%
% of Gross Profit
Research & Development $4.500M $5.050M $3.180M
YoY Change 41.51% 457.89%
% of Gross Profit
Depreciation & Amortization $0.00 $10.00K $0.00
YoY Change
% of Gross Profit
Operating Expenses $15.11M $10.60M $4.534M
YoY Change 233.22% 233.38%
Operating Profit -$15.11M -$4.534M
YoY Change 233.22%
Interest Expense $160.0K $70.00K $20.00K
YoY Change 700.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$14.95M -$10.53M -$4.511M
YoY Change 231.3% 231.69%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$14.95M -$10.53M -$4.511M
YoY Change 231.3% 226.88%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$617.3K -$2.110M -$232.5K
COMMON SHARES
Basic Shares Outstanding 20.21M
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q2 2014 Q4 2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $155.0M $104.1M $56.50M
YoY Change 174.34%
Cash & Equivalents $26.19M $21.90M $31.78M
Short-Term Investments $128.8M $82.20M $24.70M
Other Short-Term Assets $5.600M $1.900M $600.0K
YoY Change 833.33%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $160.6M $106.0M $57.10M
YoY Change 181.26% 104.65%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00 $48.00K $0.00
YoY Change 500.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $400.0K $48.00K $1.400M
YoY Change -71.43% 300.0%
Total Long-Term Assets $500.0K $96.00K $1.400M
YoY Change -64.29% 380.0%
TOTAL ASSETS
Total Short-Term Assets $160.6M $106.0M $57.10M
Total Long-Term Assets $500.0K $96.00K $1.400M
Total Assets $161.1M $106.1M $58.50M
YoY Change 175.38% 104.76%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.700M $440.0K $600.0K
YoY Change 183.33% -27.39%
Accrued Expenses $900.0K $1.200M $400.0K
YoY Change 125.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $11.60M $2.724M $2.100M
YoY Change 452.38% 78.74%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $200.0K $216.0K $200.0K
YoY Change 0.0% -6.09%
Total Long-Term Liabilities $200.0K $216.0K $200.0K
YoY Change 0.0% -6.09%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.60M $2.724M $2.100M
Total Long-Term Liabilities $200.0K $216.0K $200.0K
Total Liabilities $11.80M $2.940M $2.300M
YoY Change 413.04% 67.62%
SHAREHOLDERS EQUITY
Retained Earnings -$40.89M
YoY Change 217.39%
Common Stock $144.2M
YoY Change 6450.25%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $149.3M $103.2M $56.20M
YoY Change
Total Liabilities & Shareholders Equity $161.1M $106.1M $58.50M
YoY Change 175.38% 104.76%

Cashflow Statement

Concept 2015 Q2 2014 Q4 2014 Q2
OPERATING ACTIVITIES
Net Income -$14.95M -$10.53M -$4.511M
YoY Change 231.3% 226.88%
Depreciation, Depletion And Amortization $0.00 $10.00K $0.00
YoY Change
Cash From Operating Activities -$6.240M -$4.960M -$4.660M
YoY Change 33.91% 18.66% 339.62%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$40.00K -$10.00K
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities -$34.39M -$56.90M -$2.580M
YoY Change 1232.95%
Cash From Investing Activities -$34.39M -$56.93M -$2.570M
YoY Change 1238.13%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -4.510M 58.08M -730.0K
YoY Change 517.81% 51.17%
NET CHANGE
Cash From Operating Activities -6.240M -4.960M -4.660M
Cash From Investing Activities -34.39M -56.93M -2.570M
Cash From Financing Activities -4.510M 58.08M -730.0K
Net Change In Cash -45.14M -3.810M -7.960M
YoY Change 467.09% -111.13% 650.94%
FREE CASH FLOW
Cash From Operating Activities -$6.240M -$4.960M -$4.660M
Capital Expenditures $0.00 -$40.00K -$10.00K
Free Cash Flow -$6.240M -$4.920M -$4.650M
YoY Change 34.19% 17.7% 338.68%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q2 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
1000
CY2014Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
1000
CY2015Q2 atra License Fee Payable
LicenseFeePayable
4500000
CY2014Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
216000
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2014Q2 atra Research And Development Expense Related Party
ResearchAndDevelopmentExpenseRelatedParty
1066000
atra Research And Development Expense Related Party
ResearchAndDevelopmentExpenseRelatedParty
1066000
CY2015Q2 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
4500000
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
4500000
CY2014Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1358000
CY2014Q2 us-gaap Operating Expenses
OperatingExpenses
4534000
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4534000
CY2014Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
23000
us-gaap Interest And Other Income
InterestAndOtherIncome
316000
us-gaap Interest And Other Income
InterestAndOtherIncome
29000
CY2014Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4511000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-22000
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-14945000
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-4511000
us-gaap Net Income Loss
NetIncomeLoss
-24105000
us-gaap Depreciation
Depreciation
11000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-880000
us-gaap Share Based Compensation
ShareBasedCompensation
5053000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
34000
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19692937
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19692937
CY2015Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2015Q2 atra Liabilities Related To Indemnification Agreements
LiabilitiesRelatedToIndemnificationAgreements
0
CY2014Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4500000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-24071000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11560000
CY2015Q2 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.62
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
12774000
CY2015Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3601000
CY2015Q2 us-gaap Operating Expenses
OperatingExpenses
15108000
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-15108000
CY2015Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
163000
CY2015Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-14945000
CY2015Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-48000
CY2014Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
11000
CY2015Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-48000
CY2014Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
11000
CY2015Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14993000
CY2014Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
56714000
CY2015Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
24224000
us-gaap Depreciation
Depreciation
2000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-138000
CY2014Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
56752000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-301000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-12864000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-19836000
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31779000
us-gaap Debt Instrument Increase Accrued Interest
DebtInstrumentIncreaseAccruedInterest
2000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
24000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-1000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3314000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
264000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1162000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-29000
us-gaap Increase Decrease In Income Taxes
IncreaseDecreaseInIncomeTaxes
-92000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
3247000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
355000
atra Increase Decrease In License Fee Payable
IncreaseDecreaseInLicenseFeePayable
4500000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
28000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
27000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
111325000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
69487000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
4468000
us-gaap Repayment Of Notes Receivable From Related Parties
RepaymentOfNotesReceivableFromRelatedParties
337000
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
13500000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
12735000
atra Issuance Of Common Stock Upon Vesting Of Stock Awards
IssuanceOfCommonStockUponVestingOfStockAwards
45000
atra Change In Other Long Term Liabilities Related To Non Vested Stock Awards
ChangeInOtherLongTermLiabilitiesRelatedToNonVestedStockAwards
-40000
atra Change In Other Long Term Liabilities Related To Non Vested Stock Awards
ChangeInOtherLongTermLiabilitiesRelatedToNonVestedStockAwards
-45000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
32000
atra Offering Costs In Anticipation Of Public Filing Included In Accrued Liabilities And Accounts Payable
OfferingCostsInAnticipationOfPublicFilingIncludedInAccruedLiabilitiesAndAccountsPayable
312000
atra Offering Costs In Anticipation Of Public Filing Included In Accrued Liabilities And Accounts Payable
OfferingCostsInAnticipationOfPublicFilingIncludedInAccruedLiabilitiesAndAccountsPayable
313000
CY2015Q2 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
41927000
CY2015Q2 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
128907000
CY2015Q2 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
41915000
CY2014Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13001287
dei Entity Incorporation State Country Name
EntityIncorporationStateCountryName
Delaware
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2012-08-01
us-gaap Common Stock Conversion Basis
CommonStockConversionBasis
Nine-for-one basis
CY2015Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1451122
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1338421
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12961853
CY2015Q2 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
128907000
CY2015Q2 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
21000
CY2015Q2 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
87000
CY2015Q2 us-gaap Available For Sale Securities
AvailableForSaleSecurities
128841000
CY2014Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
82319000
CY2014Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
3000
CY2014Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
103000
CY2014Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
82219000
CY2015Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
86980000
CY2014Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
25567000
CY2014Q4 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
82319000
CY2015Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
86926000
CY2015Q2 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
128841000
CY2014Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
25505000
CY2014Q4 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
82219000
CY2015Q2 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
98226
CY2014Q4 atra Liabilities Related To Indemnification Agreements
LiabilitiesRelatedToIndemnificationAgreements
0
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent
SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
1.00
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Description And Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms
the exercise price of an option granted to a 10% shareholder cannot be less than 110% of the estimated fair value of the shares on the date of grant. Options granted to employees and non-employees generally vest over four years and expire in seven years.
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
623936
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
802099
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
2595
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
3758
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1419682
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
1419682
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
118380
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.69
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
27.09
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
12.55
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
20.44
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
21.25
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
21.25
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
17.18
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y5M12D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y5M12D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y4M6D
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
44740904
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
44740904
CY2015Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
4211691
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
15.32
CY2015Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2569000
CY2014Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
524000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5053000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3844000

Files In Submission

Name View Source Status
0001564590-15-006518-index-headers.html Edgar Link pending
0001564590-15-006518-index.html Edgar Link pending
0001564590-15-006518.txt Edgar Link pending
0001564590-15-006518-xbrl.zip Edgar Link pending
atra-10q_20150630.htm Edgar Link pending
atra-20150630.xml Edgar Link completed
atra-20150630.xsd Edgar Link pending
atra-20150630_cal.xml Edgar Link unprocessable
atra-20150630_def.xml Edgar Link unprocessable
atra-20150630_lab.xml Edgar Link unprocessable
atra-20150630_pre.xml Edgar Link unprocessable
atra-ex1032_525.htm Edgar Link pending
atra-ex311_8.htm Edgar Link pending
atra-ex312_6.htm Edgar Link pending
atra-ex321_9.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g20150806214815658902.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending